FundingHealthcare & Life Sciences
Immuneel raises ₹100 Cr in Series B
By Abha Lohia · Editor ·
Immuneel Therapeutics: funding and every story →
series-bBengaluruFounded 2018
- Immuneel Therapeutics develops cell and gene therapies for cancer
- It raised over ₹100 Cr in Series B from Singularity AMC, Rainmatter, and existing investors
- Funds will scale manufacturing, advance pipeline, and expand into Asia Pacific and Middle East
What happened
- Immuneel Therapeutics raised over ₹100 Cr in a Series B funding round.
- New investors Singularity AMC and Rainmatter by Zerodha participated.
- Existing investors Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital also invested.
- The company will use the funds to scale GMP manufacturing capacity.
- It will also advance next-gen cell and gene therapy pipeline.
- A significant portion will go toward commercialisation of Qartemi.
- Immuneel plans to expand into Asia Pacific and Middle East markets.
Why it matters
- India's gene therapy sector is growing with startups like Cellogen and Oncare raising funds.
- China has hundreds of gene therapy companies, while India's biotech boom is recent.
- Government funding and evolving investor/regulatory ecosystem are driving momentum.
- CEO cautions long-term success requires manufacturing, supply chains, and GTM strategies beyond science.
The business
- Immuneel commercialised Qartemi, a CAR-T therapy for Non-Hodgkin Lymphoma.
- CAR-T therapy modifies a patient's own immune cells to attack cancer.
- Non-Hodgkin Lymphoma is a blood cancer of the lymphatic system.
- The company currently treats lymphoma patients in India; leukemia treatment to start soon.
- Solid tumor programs are in research, not yet in clinic.
- It operates India's first internationally benchmarked CAR-T platform.
- Over 100 patients have been treated since commercial launch in late 2024.
- Immuneel aims to offer therapy at less than 10% of Western cost of $400,000–$500,000 per patient.
The founders
KM
Kiran Mazumdar-Shaw
co-founder, existing investor- Co-founder of Immuneel Therapeutics.
- Also an existing investor in the company.
KM
Kush M Parmar
co-founder- Co-founder of Immuneel Therapeutics.
SM
Siddhartha Mukherjee
co-founder- Co-founder of Immuneel Therapeutics.
Who put in money
- Singularity AMC new investor — An asset management company.
- Rainmatter by Zerodha new investor — An investment arm of Zerodha.
- Kiran Mazumdar-Shaw existing investor — Co-founder of Immuneel Therapeutics and a prominent biotech entrepreneur.
- Eight Roads Ventures existing investor — A venture capital firm.
- F-Prime Capital existing investor — A venture capital firm.
In numbers
₹100 CrFunding raised · 2026
over 100Patients treated · 2024-2026
~$38 MnTotal funding to date · 2026
$400,000-$500,000Western cost per patient
What happens next
- Scale GMP manufacturing capacity.
- Advance next-gen cell and gene therapy pipeline.
- Expand into Asia Pacific and Middle East markets.
- Commercialise Qartemi further.
- Pursue clinical co-development partnerships in Australia and Southeast Asia.
Earlier rounds
- 2024 · extended Series A · ₹100 Cr · led by Taiba Middle East FZ LLC
- April 2022 · Series A · ~$15 Mn
Up against
CellogenOncare
Words to know
- CAR-T therapy
- Chimeric Antigen Receptor T-cell therapy: a treatment that modifies a patient's own immune cells to attack cancer cells.
- Non-Hodgkin Lymphoma
- A type of blood cancer that starts in the lymphatic system.
- GMP manufacturing
- Good Manufacturing Practice: a system ensuring products are consistently produced and controlled according to quality standards.
- Series B
- A later-stage funding round for scaling operations, typically after Series A.
The numbers around it
Healthcare & Life Sciences in June 2026: 11 rounds with a disclosed amount, $118 million in all; the biggest was Vetic ($40 Mn). Every sector this year →
Other articles talking about it
Terms in this story
- Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
- Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on Immuneel Therapeutics → · All startup news on 8 June 2026 →
Is this Immuneel Therapeutics? Get your “Featured on StopDown” badge →